Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.
about
Trial watch - inhibiting PARP enzymes for anticancer therapyPARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogeneNHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.PARP inhibition causes premature loss of cohesion in cancer cells.The Association between PARP1 and LIG3 Expression Levels and Chromosomal Translocations in Acute Myeloid Leukemia Patients.Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy
P2860
Q26745673-8E068F06-27A7-4BC3-A375-5F9C5F529333Q35228413-65926558-40EC-4A30-AB00-38F9EC5AEDE9Q35735341-0E7D251B-E196-4BC7-A1E3-2571EF9F374BQ35870483-5848DF7D-950A-43F8-9BF4-D8A91F5FC179Q36413813-AF035DFE-051D-46F7-82A9-518177858841Q42371576-2B98FA5A-7921-4530-A605-57E071D1984EQ47270169-DAA52B63-8438-4B44-8893-1CF6A896F2BEQ55401060-8690AD60-58A8-40CE-8310-5DFD27BBEB4BQ57788820-AB81290C-99E9-4348-AC79-BC8A57473F4B
P2860
Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Variations in the mRNA express ...... nd impact on clinical outcome.
@en
Variations in the mRNA express ...... nd impact on clinical outcome.
@nl
type
label
Variations in the mRNA express ...... nd impact on clinical outcome.
@en
Variations in the mRNA express ...... nd impact on clinical outcome.
@nl
prefLabel
Variations in the mRNA express ...... nd impact on clinical outcome.
@en
Variations in the mRNA express ...... nd impact on clinical outcome.
@nl
P2093
P2860
P50
P356
P1476
Variations in the mRNA express ...... and impact on clinical outcome
@en
P2093
Aurélie Susini
Janet Hall
Keltouma Driouch
Rosette Lidereau
Tomasz Zaremba
P2860
P304
P356
10.1002/IJC.28304
P577
2013-08-09T00:00:00Z